HOUSE DOCKET, NO. 2588        FILED ON: 2/18/2021

HOUSE  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  No. 1279

 

The Commonwealth of Massachusetts

_________________

PRESENTED BY:

Bradley H. Jones, Jr.

_________________

To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General
Court assembled:

The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill:

An Act establishing a commission to review contracts between pharmaceutical benefit managers and MassHealth.

_______________

PETITION OF:

 

Name:

District/Address:

Date Added:

Bradley H. Jones, Jr.

20th Middlesex

2/8/2021

Susan Williams Gifford

2nd Plymouth

2/25/2021

Angelo L. D'Emilia

8th Plymouth

2/26/2021

Paul K. Frost

7th Worcester

3/11/2021

Hannah Kane

11th Worcester

3/18/2021

Kimberly N. Ferguson

1st Worcester

3/22/2021

Mathew J. Muratore

1st Plymouth

3/25/2021

Steven S. Howitt

4th Bristol

3/30/2021


HOUSE DOCKET, NO. 2588        FILED ON: 2/18/2021

HOUSE  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  No. 1279

By Mr. Jones of North Reading, a petition (accompanied by bill, House, No. 1279) of Bradley H. Jones, Jr., and others for an investigation by a special commission (including members of the General Court) relative to contracts between the MassHealth program and pharmaceutical benefit managers.  Health Care Financing.

 

The Commonwealth of Massachusetts

 

_______________

In the One Hundred and Ninety-Second General Court
(2021-2022)

_______________

 

An Act establishing a commission to review contracts between pharmaceutical benefit managers and MassHealth.

 

Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority of the same, as follows:
 

SECTION 1. Notwithstanding any general or special law to the contrary, there shall be a special commission established to assess contracts between the MassHealth program and pharmaceutical benefit managers. The commission shall be tasked with, but not be limited to, evaluating the possible transition of MassHealth from its existing drug purchasing contract model with pharmaceutical benefit managers to a pass-through model.

The commission shall consist of 10 members: the state auditor, or a designee; the secretary of health and human services, or a designee; the director of MassHealth, or a designee; the director of insurance, or a designee; the speaker of the house of representatives, or a designee; the senate president, or a designee; the minority leader of the house of representatives, or a designee; the minority leader of the house, or a designee; one member who shall advocate on behalf of pharmaceutical benefit managers, to be appointed by the governor; and one member who shall advocate on behalf of pharmacies, to be appointed by the governor.

The commission shall submit its report and findings, along with any draft of legislation, to the house and senate committees on ways and means, the joint committee on health care financing, and the clerks of the house of representatives and the senate within 1 year of the passage of this act.